ZLD
Zelira Therapeutics Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-18.88%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
6
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. The company owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. The company has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
📈 Performance
Price History
+40.00%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.49
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ZLD
6
📊 Total Capital Earnings
$4K
🔃 Average investment frequency
55 weeks
💵 Average investment amount
$470
⏰ Last time a customer invested in ZLD
86 days
ZLD investor breakdown
💵 Income of investors
More than 200k
150k - 200k
17%
100k - 150k
17%
50k - 100k
33%
Less than 50k
33%
👶 Age of investors
18 - 25
26 - 34
33%
35 - 90
67%
🙋 Legal gender of investors
Female
67%
Male
33%
Pearlers who invest in ZLD also invest in...
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
3.37%
📊 Share price
$69.61 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
10.15%
📊 Share price
$16.22 AUD
💸 FINANCIALS
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
Incannex Healthcare Ltd. is a clinical stage pharmaceutical development company, which engages in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2007-05-23. The firm is engaged in the research and development associated with medicinal cannabinoid and psychedelic pharmaceutical products and therapies. The firm targets five indications: obstructive sleep apnea (OSA), traumatic brain injury and concussion (TBI), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and inflammatory lung conditions. Its drug candidates include IHL-42X, IHL-216A, Psilocybin-assisted psychotherapy for general anxiety disorder (Psi-GAD) and IHL-675A. Its IHL-42X is a cannabinoid combination product for treatment of OSA. Its IHL-675A comprises a combination of hydroxychloroquine and CBD for prevention and treatment of inflammatory lung conditions, rheumatoid arthritis and inflammatory bowel diseases. IHL-216A is a cannabinoid combination product for the treatment of TBI. The company is investigating the use of psilocybin-assisted psychotherapy to treat GAD.
🙌 Performance (5Yr p.a)
21.00%
📊 Share price
$0.04 AUD
NULL STOCK
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6966.81m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
3.65%
📊 Share price
$138.15 AUD
💸 FINANCIALS
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
🙌 Performance (5Yr p.a)
8.06%
📊 Share price
$36.73 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
🌏 GLOBAL
Want more shares? Try these...
